Details

Autor(en) / Beteiligte

• Bozkurt, Ceyhun
• Hazar, Volkan
• Malbora, Barış
• Küpesiz, Alphan
• Aygüneş, Utku
• Fışgın, Tunç
• Karakükçü, Musa
• Kuşkonmaz, Barış
• Kılıç, Suar Çakı
• Bayırlı, Derya
• Arman Bilir, Özlem
• Yalçın, Koray
• Gözmen, Salih
• Uygun, Vedat
• Elli, Murat
• Sarbay, Hakan
• Küpesiz, Funda Tayfun
• Şaşmaz, Hatice İlgen
• Aksoy, Başak Adaklı
• Yılmaz, Ebru
• Okur, Fatma Visal
• Tekkeşin, Funda
• Yenigürbüz, Fatma Demir
• Özek, Gülcihan
• Atay, Abdullah Avni
• Bozkaya, İkbal Ok
• Çelen, Suna
• Öztürkmen, Seda
• Güneş, Adalet Meral
• Gürsel, Orhan
• Güler, Elif
• Özcan, Alper
• Çetinkaya, Duygu Uçkan
• Aydoğdu, Selime
• Özbek, Namık Yaşar
• Karasu, Gülsün
• Sezgin, Gülay
• Doğru, Ömer
• Albayrak, Davut
• Öztürk, Gülyüz
• Aksoylar, Serap
• Daloğlu, Hayriye
• Odaman Al, Işık
• Evim, Melike Sezgin
• Akbayram, Sinan
• Öncül, Yurday
• Zengin, Emine
• Albayrak, Canan
• Timur, Çetin
• Kar, Yeter Düzenli
• Çakmaklı, Hasan Fatih
• Tüfekçi, Özlem
• Töret, Ersin
• Antmen, Bülent

Titel

COVID‐19 disease in children and adolescents following allogeneic hematopoietic stem cell transplantation: A report from the Turkish pediatric bone marrow transplantation study group

Ist Teil von

• Pediatric transplantation, 2024-05, Vol.28 (3), p.e14758-n/a

Ort / Verlag

Denmark: Wiley Subscription Services, Inc

Erscheinungsjahr

2024

Quelle

Wiley Online Library - AutoHoldings Journals

Beschreibungen/Notizen

• Background Data on the risk factors and outcomes for pediatric patients with SARS‐CoV‐2 infection (COVID‐19) following hematopoietic stem cell transplantation (HSCT) are limited. Objectives The study aimed to analyze the clinical signs, risk factors, and outcomes for ICU admission and mortality in a large pediatric cohort who underwent allogeneic HSCT prior to COVID‐19 infection. Method In this nationwide study, we retrospectively reviewed the data of 184 pediatric HSCT recipients who had COVID‐19 between March 2020 and August 2022. Results The median time from HSCT to COVID‐19 infection was 209.0 days (IQR, 111.7–340.8; range, 0–3845 days). The most common clinical manifestation was fever (58.7%). While most patients (78.8%) had asymptomatic/mild disease, the disease severity was moderate in 9.2% and severe and critical in 4.4% and 7.6%, respectively. The overall mortality was 10.9% (n: 20). Deaths were attributable to COVID‐19 in nine (4.9%) patients. Multivariate analysis revealed that lower respiratory tract disease (LRTD) (OR, 23.20, p: .001) and lymphopenia at diagnosis (OR, 5.21, p: .006) were risk factors for ICU admission and that HSCT from a mismatched donor (OR, 54.04, p: .028), multisystem inflammatory syndrome in children (MIS‐C) (OR, 31.07, p: .003), and LRTD (OR, 10.11, p: .035) were associated with a higher risk for COVID‐19‐related mortality. Conclusion While COVID‐19 is mostly asymptomatic or mild in pediatric transplant recipients, it can cause ICU admission in those with LRTD or lymphopenia at diagnosis and may be more fatal in those who are transplanted from a mismatched donor and those who develop MIS‐C or LRTD. COVID‐19 in children following HSCT is frequently asymptomatic/mild. Nonetheless, 12% of patients have such severe disease that they need intensive care. Adverse outcomes are expected in mismatched HSCT, lymphopenia, LRTD, and MIS‐C.